59results about "Cytokeratin" patented technology

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to improve the efficacy of fertilizer usage and absorption by soybeans. By selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and then infused to the fertilized soil in which the soybean seeds are grown, as well as the plants after the seed start sprouting. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, for applying to the soil around the soybean.

Relates to the technical field of medicines, provides keratin CF5, a preparation method, a pharmaceutical composition and application thereof, and particularly relates to keratin CF5, a nucleic acid molecule for coding the keratin CF5, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF5. The invention relates to a keratin CF5-containing pharmaceutical composition and application of the keratin CF5, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF5, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

Belongs to the technical field of medicine, and provides keratin CF7, a preparation method, a pharmaceutical composition and application thereof. Specifically, the invention provides keratin CF7, a nucleic acid molecule encoding the keratin CF7, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF7, a pharmaceutical composition containing the keratin CF7, and a preparation method of the keratin CF7. The invention also discloses application of the keratin CF7, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating, anti-convulsion, anti-epilepsy, antihypertensive, anti-inflammatory and antiviral drugs.

The invention provides keratin CF3 as well as a preparation method, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention provides keratin CF3, a nucleic acid molecule encoding the keratin CF3, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF3, a pharmaceutical composition containing the keratin CF3, and a preparation method of the keratin CF3. The invention also discloses application of the keratin CF3, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

The invention provides keratin CF4 as well as a preparation method, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention provides keratin CF4, a nucleic acid molecule encoding the keratin CF4, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF4, a pharmaceutical composition containing the keratin CF4, and a preparation method of the keratin CF4. The invention also discloses application of the keratin CF4, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

Belongs to the technical field of medicines, and relates to keratin CF1, a preparation method, a pharmaceutical composition and application thereof, in particular to keratin CF1, a nucleic acid molecule for encoding keratin CFI, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF1. The invention relates to a keratin CF1-containing pharmaceutical composition and application of the keratin CF1, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF1, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

Belongs to the technical field of medicines, discloses keratin CF2, a preparation method, a pharmaceutical composition and application thereof, and particularly relates to keratin CF2, a nucleic acid molecule for encoding the keratin CF2, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF2. The invention relates to a keratin CF2-containing pharmaceutical composition and application of the keratin CF2, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF2, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

Belongs to the technical field of medicine, and provides keratin CF8, a preparation method, a pharmaceutical composition and application thereof. Provided are a keratin CF8, a nucleic acid molecule encoding the keratin CF8, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF8, and a pharmaceutical composition containing the keratin CF8. The invention also discloses application of the keratin CF8, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating, anti-convulsion, anti-epilepsy, antihypertensive, anti-inflammatory and antiviral drugs.

The present invention provides a keratin BD-13, an encoding nucleic acid molecule, an expression vector, a host cell, a preparation method thereof, and a pharmaceutical composition containing the keratin. The keratin BD-13 can be used in the preparation of medicamnet for antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, anti-hypertension, anti-inflammatory, and antiviral.

The invention belongs to the technical field of medicines, and relates to keratin CF12, a preparation method, a pharmaceutical composition and application thereof. Relates to a keratin CF12, a nucleic acid molecule for coding the keratin CF12, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF12, and a pharmaceutical composition containing the keratin CF12. The invention also discloses application of the keratin CF12, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

Provided herein is a method of improving the solubility of a recombinantly produced polypeptide of interest, by expressing the polypeptide of interest together with a solubility-enhancing amino acid sequence.

The application provides a KRT31 gene knockout cell line and its application in promoting replication of viruses of the Picornaviridae family and / or production of vaccines of viruses of the Picornaviridae family, and belongs to the technical field of genetic engineering. The application provides an application of a KRT31 gene or a coded protein thereof as a target in preparation of a product for regulating replication of viruses of the Picornaviridae family and / or vaccine production. Up-regulation of the expression level of the KRT31 gene can inhibit replication of viruses of the Picornaviridae family, and down-regulation of the expression level of the KRT31 gene can promote replication of viruses of the Picornaviridae family. The application adopts sgRNA to knockout the KRT31 gene to prepare a cell line with lost function of a gene coded protein, so as to promote replication of viruses of the Picornaviridae family, improve virus titer and antigen yield, and help to efficiently prepare vaccines of viruses of the Picornaviridae family.

Provided herein are fusion proteins / peptides and biopolymers comprising keratin and keratin associated peptide sequences. The fusion proteins and biopolymers may further comprise elastin-like, silk-like, collagen or collagen-like, resilin-like, abductin-like peptide, and / or linker-like sequences. The fusion proteins and biopolymers may exhibit the functional properties derived from each of the various peptide sequences incorporated therein, like elasticity, hydration, recovery, texture, or antimicrobial and UV protections. Additionally, provided herein are methods for obtaining and characterization of fusion proteins and biopolymers comprising keratin and keratin associated peptide sequences. The fusion proteins and biopolymers comprising keratin and keratin associated peptide sequences may be included in compositions for improving the properties of hair, skin, and nails.

The present invention relates to the technical field of medicines, provides a keratin CF5, a preparation method, a pharmaceutical composition containing same, and a use of the keratin CF5, and specifically relates to a keratin CF5, a nucleic acid molecule encoding the keratin CF5, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or the nucleic acid molecule integrated into a genome, a preparation method for the keratin CF5, a pharmaceutical composition containing the keratin CF5, and a use of the keratin CF5, the nucleic acid molecule, the expression vector, the host cell, or the pharmaceutical composition in preparation of drugs having antipyretic and analgesic, antitussive and expectorant, anticonvulsant, antiepileptic, antihypertensive, anti-inflammatory and antiviral effects.

Provided herein are compositions comprising a polypeptide and an excipient, wherein the polypeptide comprises a keratin or keratin associated peptide block and one or more polypeptide blocks. In some embodiments, the excipient comprises an emollient, an emulsifier, a conditioning agent, vitamin E or derivative thereof, a ceramide, a lipid nanoparticle dispersion, a hair conditioner, a skin conditioner, a cleansing agent, a detoxifying agent, or a combination thereof. Provided herein are methods for using the compositions for treating hair.

The invention belongs to the technical field of medicines, and relates to keratin CF14, a nucleic acid molecule encoding the keratin CF14, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF14, a pharmaceutical composition containing the keratin CF14, and a preparation method of the keratin CF14. The invention also discloses application of the keratin CF14, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

The present invention relates to the technical field of medicines, provides a keratin CF7, a preparation method therefor, a pharmaceutical composition containing same, and a use of keratin CF7, and specifically provides keratin CF7, a nucleic acid molecule encoding keratin CF7, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or the nucleic acid molecule integrated into a genome, a preparation method for keratin CF7, a pharmaceutical composition containing keratin CF7, and a use of keratin CF7, the nucleic acid molecule, the expression vector, the host cell, or the pharmaceutical composition in preparation of drugs having antipyretic and analgesic, antitussive and expectorant, anticonvulsant, antiepileptic, antihypertensive, anti-inflammatory and antiviral effects.

The present invention provides a non-human animal having a novel fiber and a method for preparing the non-human animal. Specifically, the present invention provides a non-human animal with reduced expression or functions of at least one gene constituting the Krt or KAP family, and a method for preparing the non-human animal.

Disclosed herein are methods, uses and compositions for the treatment or prophylaxis of cancer in a mammalian subject comprising administering to the subject an amount of an agent which targets an extracellular portion of KRT14 or its functional homolog or variant thereof resident on cancer cells or an agent which induces production of an antagonist of the extracellular portion of KRT14 or its functional homolog or variant on cancer cells. The present disclosure also extends to methods of monitoring and / or diagnosing cancer in a subject.

Fusion proteins / peptides and biopolymers containing keratin and keratin-related peptide sequences are provided herein. The fusion proteins and biopolymers may further comprise elastin-like, silk-like, collagen or collagen-like, resilin-like, abductin-like peptides, and / or linker-like sequences. The fusion proteins and biopolymers may exhibit functional properties derived from the various peptide sequences incorporated therein, such as elasticity, moisture retention, recovery, texture, or antibacterial and UV protection. Additionally, methods for obtaining and characterizing fusion proteins and biopolymers containing keratin and keratin-related peptide sequences are provided herein. Fusion proteins and biopolymers containing keratin and keratin-related peptide sequences can be included in compositions for improving the properties of hair, skin, and nails.

The present disclosure relates to a process to assemble proteins derived from platelet lysates in bioactive microparticles, with increased surface organization. The present invention further relates to protein-based biomaterials applicable to biomedical and biotechnology fields, more precisely in tissue engineering strategies, disease modeling, and other biomedical applications. Namely, a method for obtaining a protein microparticle from a platelet lysate comprising the following steps: lyophilizing the platelet lysate; dissolving the lyophilized platelet lysate in phosphate buffer saline to obtain a platelet lysate solution; adding a reducing agent to the platelet lysate solution to obtain a reduced platelet lysate solution; adding an oxidizing agent to the reduced platelet lysate solution to form the microparticles by precipitation.

Pest deterrent compositions are provided that at least one keratin protein isolated from human hair and at least one carrier. The pest deterrent compositions provide an environmentally friendly and biodegradable alternative to traditional chemicals and biologicals. The pest deterrent compositions are suitable for preventing damage to or consumption of crops by pests.

The invention relates to a method for producing keratin powder of the protein β-keratin from feathers of animal origin by extracting keratin, filtering the extraction solution and obtaining a colloidal solution, and drying same to form the keratin powder. The invention also relates to a colloidal solution for topical application containing keratin particles of the protein β-keratin and / or agglomerates thereof or a keratin powder containing said keratin particles. The colloidal solution and the keratin powder are used for the production of preparations with therapeutic, diagnostic, preventative or cosmetic purposes for humans and / or animals.

The invention relates to the field of keratin extraction methods. More particularly, the invention relates to a method for "green" extraction of animal-based keratin from sheep's wool. The aim of this industrialisable method is to produce a chemically pure hydrolysate of animal keratin, from the wool wash to the extracted hydrolysate.

The present invention concerns an isolated recombinant nucleic acid molecule comprising at least one nucleic acid sequence encoding at least one mink hair keratin protein and further comprising a heterologous promoter controlling the expression of said at least one nucleic acid sequence, as well as an expression vector comprising said nucleic acid molecule, a host cell comprising said nucleic acid molecule or said expression vector and a method of production of mink hair keratin protein using said nucleic acid molecule.

The invention discloses a construction method and application of an animal model with insufficient bladder activity and fibrosis, and belongs to the technical field of biology. The construction method comprises the following steps: constructing a Krt20-Cre-tdTomato mouse strain Krt20-Cre-tdTomato through a gene editing technology, and specifically, inserting a Cre-2A-tdTomato-Wpre-pA sequence into a first exon of a Krt20 gene by adopting a CRISPR / Cas9 mediated homologous recombination technology, and constructing the Krt20-Cre-tdTomato mouse strain which can be used as an animal model with insufficient bladder activity and fibrosis. The method is applied to the research of screening medicines for treating bladder activity deficiency and bladder fibrosis. According to the method, the problems that the existing lower urinary tract symptom modeling process is complicated and the model types are insufficient are solved, and the constructed bladder activity deficiency and fibrosis animal model can provide a basis and a preclinical animal model for screening potential drug targets.

The invention relates to a fast, easy, low-cost method optimized for the extraction of keratin from human hair and the keratin obtained by this method. In said method, the need for centrifugation, a second filtering process, and the use of excess chemicals is eliminated, and thus the method can be carried out at low cost. With said method, keratin reduced to small filaments is obtained, thus making the use of keratin as a biomaterial easier.